This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-icotrokinra-moderate-severe-plaque-psoriasis-2026a10008c8?src=rss
Author :
Publish date : 2026-03-18 18:15:00
Copyright for syndicated content belongs to the linked Source.
